The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Molecular Diagnostic Testing (January 2021)
Open accessAbstract
Background: Accurate molecular diagnostic tests are necessary for confirming a diagnosis of coronavirus disease 2019 (COVID-19). Direct detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acids in respiratory tract specimens informs patient, healthcare institution and public health level decision-making. The numbers of available SARS-CoV-2 nucleic acid detection tests are rapidly increasing, as is the COVID-19 diagnostic literature. Thus, the Infectious Diseases Society of America (IDSA) recognized a significant need for frequently updated systematic reviews of the literature to inform evidence-based best practice guidance. Objective: The IDSA’s goal was to develop an evidence-based diagnostic guideline to assist clinicians, clinical laboratorians, patients and policymakers in decisions related to the optimal use of SARS-CoV-2 nucleic acid amplification tests. In addition, we provide a conceptual framework for understanding molecular diagnostic test performance, discuss the nuance of test result interpretation in a variety of practice settings and highlight important unmet research needs in the COVID-19 diagnostic testing space. Methods: IDSA convened a multidisciplinary panel of infectious diseases clinicians, clinical microbiologists, and experts in systematic literature review to identify and prioritize clinical questions and outcomes related to the use of SARS-CoV-2 molecular diagnostics. Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to assess the certainty of evidence and make testing recommendations. Results: The panel agreed on 17 diagnostic recommendations. Conclusions: Universal access to accurate SARS-CoV-2 nucleic acid testing is critical for patient care, hospital infection prevention and the public response to the COVID-19 pandemic. Information on the clinical performance of available tests is rapidly emerging, but the quality of evidence of the current literature is considered moderate to very low. Recognizing these limitations, the IDSA panel weighed available diagnostic evidence and recommends nucleic acid testing for all symptomatic individuals suspected of having COVID-19. In addition, testing is recommended for asymptomatic individuals with known or suspected contact with a COVID-19 case. Testing asymptomatic individuals without known exposure is suggested when the results will impact isolation/quarantine/personal protective equipment (PPE) usage decisions, dictate eligibility for surgery, or inform solid organ or hematopoietic stem cell transplantation timing. Ultimately, prioritization of testing will depend on institutional-specific resources and the needs of different patient populations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies
Whiting, P. F., Rutjes, A. W. S., Westwood, M. E., Mallett, S., Deeks, J. J., Reitsma, J. B., Leeflang, M. M. G., Sterne, J. A. C., Bossuyt, P. M. M., & the QUADAS-2 Group* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-8-201110180-00009 · Cited by 14,199
Virological assessment of hospitalized patients with COVID-2019
Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2196-x · Cited by 6,661
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
How to perform a meta-analysis with R: a practical tutorial
Balduzzi, S., Rücker, G., & Schwarzer, G. (2019) · Evidence Based Mental Health · doi:10.1136/ebmental-2019-300117 · Cited by 5,827
Reitsma, J. B., Glas, A. S., Rutjes, A. W. S., Scholten, R. J. P. M., Bossuyt, P. M., & Zwinderman, A. H. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.02.022 · Cited by 3,369
GRADE guidelines: 2. Framing the question and deciding on important outcomes
Guyatt, G. H., Oxman, A. D., Kunz, R., Atkins, D., Brozek, J., Vist, G., Alderson, P., Glasziou, P., Falck-Ytter, Y., & Schünemann, H. J. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.09.012 · Cited by 1,911
Self-citationClinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
Kuderer, N. M., Choueiri, T. K., Shah, D. P., Shyr, Y., Rubinstein, S. M., Rivera, D. R., Shete, S., Hsu, C.-Y., Desai, A., de Lima Lopes, G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31187-9 · Cited by 1,726
Dai, M., Liu, D., Liu, M., Zhou, F., Li, G., Chen, Z., Zhang, Z., You, H., Wu, M., Zheng, Q., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0422 · Cited by 1,589
Viral load of SARS-CoV-2 in clinical samples.
Pan, Y., Zhang, D., Yang, P., Poon, L. L. M., & Wang, Q. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30113-4 · Cited by 1,562
Spread of SARS-CoV-2 in the Icelandic population
Gudbjartsson, D. F., Helgason, A., Jonsson, H., Magnusson, O. T., Melsted, P., Norddahl, G. L., Saemundsdottir, J., Sigurdsson, A., Sulem, P., Agustsdottir, A. B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2006100 · Cited by 1,248
Research works printed but not linked: 159
- Zhu, 2020, A novel coronavirus from patients with Pneumonia in China, 2019, N Engl J Med, 382, 727, 10.1056/NEJMoa2001017 · DOI · Paper page
- Lu, 2020, Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding, Lancet, 395, 565, 10.1016/S0140-6736(20)30251-8 · DOI · Paper page
- Gorbalenya, 2020, The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2, Nat Microbiol, 5, 536, 10.1038/s41564-020-0695-z · DOI · Paper page
- Burke, 2020, Symptom profiles of a convenience sample of patients with COVID-19—United States, January–April 2020, Morb Mortal Wkly Rep, 69, 904, 10.15585/mmwr.mm6928a2 · DOI · Paper page
- Morgan, 2018, Development of rapid guidelines: 3. GIN-McMaster guideline development checklist extension for rapid recommendations, Health Res Policy Syst, 16, 63, 10.1186/s12961-018-0330-0 · DOI
- Hanson, 2020, Infectious Diseases Society of America Guidelines on the diagnosis of coronavirus disease 2019 (COVID-19): serologic testing, Clin Infect Dis, ciaa1343
- Doebler, 2020, mada: meta-analysis of diagnostic accuracy. R package 0.5.10. ed
- Team RC, 2020, R: a language and environment for statistical computing
- Schünemann, 2020, GRADE guidelines: 21 part 1. Study design, risk of bias, and indirectness in rating the certainty across a body of evidence for test accuracy, J Clin Epidemiol, 122, 129, 10.1016/j.jclinepi.2019.12.020 · DOI · Paper page
- Schünemann, 2020, GRADE guidelines: 21 part 2. Test accuracy: inconsistency, imprecision, publication bias, and other domains for rating the certainty of evidence and presenting it in evidence profiles and summary of findings tables, J Clin Epidemiol, 122, 142, 10.1016/j.jclinepi.2019.12.021 · DOI · Paper page
- Ai, 2020, Optimizing diagnostic strategy for novel coronavirus pneumonia, a multi-center study in Eastern China, 10.1101/2020.02.13.20022673 · DOI
- Alexander, 2014, World Health Organization recommendations are often strong based on low confidence in effect estimates, J Clin Epidemiol, 67, 629, 10.1016/j.jclinepi.2013.09.020 · DOI
- Guyatt, 2016, Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group, J Clin Epidemiol, 80, 3, 10.1016/j.jclinepi.2016.07.006 · DOI · Paper page
- Bordi, 2020, Differential diagnosis of illness in patients under investigation for the novel coronavirus (SARS-CoV-2), Italy, February 2020, Euro Surveill, 25, 2000170, 10.2807/1560-7917.ES.2020.25.8.2000170 · DOI
- Hsih, 2020, Featuring COVID-19 cases via screening symptomatic patients with epidemiologic link during flu season in a medical center of central Taiwan, J Microbiol Immunol Infect, 53, 459, 10.1016/j.jmii.2020.03.008 · DOI
- Liu, 2020, Positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in Wuhan, China, from Jan to Feb 2020, Clin Chim Acta, 505, 172, 10.1016/j.cca.2020.03.009 · DOI · Paper page
- Tolia, 2020, Preliminary results of initial testing for coronavirus (COVID-19) in the Emergency Department, West J Emerg Med, 21, 503, 10.5811/westjem.2020.3.47348 · doi:10.5811/westjem.2020.3.47348
- Pu, 2020, Screening and managing of suspected or confirmed novel coronavirus (COVID-19) patients: experiences from a tertiary hospital outside Hubei province, 10.1101/2020.03.20.20038679 · DOI
- Huang, 2020, Triaging patients in the outbreak of the 2019 novel coronavirus, 10.1101/2020.03.13.20035212 · doi:10.1101/2020.03.13.20035212
- Azzi, 2020, Rapid Salivary Test suitable for a mass screening program to detect SARS-CoV-2: a diagnostic accuracy study, J Infect, 81, e75, 10.1016/j.jinf.2020.06.042 · DOI
- Hanson, 2020, Self-collected anterior nasal and saliva specimens versus healthcare worker-collected nasopharyngeal swabs for the molecular detection of SARS-CoV-2, J Clin Microbiol, 58, e01824-20, 10.1128/JCM.01824-20 · doi:10.1128/jcm.01824-20
- Iwasaki, 2020, Comparison of SARS-CoV-2 detection in nasopharyngeal swab and saliva, J Infect, 81, e145, 10.1016/j.jinf.2020.05.071 · DOI · Paper page
- Landry, 2020, Challenges in use of saliva for detection of SARS CoV-2 RNA in symptomatic outpatients, J Clin Virol, 130, 104567, 10.1016/j.jcv.2020.104567 · DOI
- Leung, 2021, Deep throat saliva as an alternative diagnostic specimen type for the detection of SARS-CoV-2, J Med Virol, 93, 533, 10.1002/jmv.26258 · doi:10.1002/jmv.26258
- McCormick-Baw, 2020, Saliva as an alternate specimen source for detection of SARS-CoV-2 in symptomatic patients using cepheid xpert xpress SARS-CoV-2, J Clin Microbiol, 58, e01109, 10.1128/JCM.01109-20 · DOI
- McCulloch, 2020, Comparison of unsupervised home self-collected midnasal swabs with clinician-collected nasopharyngeal swabs for detection of SARS-CoV-2 infection, JAMA Netw Open, 3, e2016382, 10.1001/jamanetworkopen.2020.16382 · DOI · Paper page
- Migueres, 2020, Saliva sampling for diagnosing SARS-CoV-2 infections in symptomatic patients and asymptomatic carriers, J Clin Virol, 130, 104580, 10.1016/j.jcv.2020.104580 · doi:10.1016/j.jcv.2020.104580
- Otto, 2020, Posterior oropharyngeal salivafor the detection of SARS-CoV-2, Clin Infect Dis, ciaa1181
- Patel, 2020, Performance of oropharyngeal swab testing compared to nasopharyngeal swab testing for diagnosis of COVID-19 - United States, January 2020 - February 2020, Clin Infect Dis, 72, 482, 10.1093/cid/ciaa759 · doi:10.1093/cid/ciaa759
- Pham, 2020, Performance characteristics of a high-throughput automated transcription-mediated amplification test for SARS-CoV-2 detection, J Clin Microbiol, 58, e01669-20, 10.1128/JCM.01669-20 · doi:10.1128/jcm.01669-20
- Procop, 2021, A comparison of five SARS-CoV-2 molecular assays with clinical correlations, Am J Clin Pathol, 155, 69, 10.1093/ajcp/aqaa181 · doi:10.1093/ajcp/aqaa181
- Tu, 2020, Swabs collected by patients or health care workers for SARS-CoV-2 testing, N Engl J Med, 383, 494, 10.1056/NEJMc2016321 · DOI · Paper page
- Vermeiren, 2020, Comparison of copan ESwab and FLOQSwab for COVID-19 diagnosis: working around a supply shortage, J Clin Microbiol, 58, e00669-20, 10.1128/JCM.00669-20 · doi:10.1128/jcm.00669-20
- Wang, 2020, Comparison of nasopharyngeal and oropharyngeal swabs for SARS-CoV-2 detection in 353 patients received tests with both specimens simultaneously, Int J Infect Dis, 94, 107, 10.1016/j.ijid.2020.04.023 · DOI · Paper page
- Williams, 2020, Saliva as a noninvasive specimen for detection of SARS-CoV-2, J Clin Microbiol, 58, e00776-20, 10.1128/JCM.00776-20 · DOI · Paper page
- Yokota, 2020, Mass screening of asymptomatic persons for SARS-CoV-2 using saliva, Clin Infect Dis, ciaa1388
- LeBlanc, 2020, A combined oropharyngeal/nares swab is a suitable alternative to nasopharyngeal swabs for the detection of SARS-CoV-2, J Clin Virol, 128, 104442, 10.1016/j.jcv.2020.104442 · DOI
- Pere, 2020, Nasal swab sampling for SARS-CoV-2: a convenient alternative in times of nasopharyngeal swab shortage, J Clin Microbiol, 58, e00721-20, 10.1128/JCM.00721-20 · DOI
- Vlek, 2021, Combined throat/nasal swab sampling for SARS-CoV-2 is equivalent to nasopharyngeal sampling, Eur J Clin Microbiol Infect Dis, 40, 193, 10.1007/s10096-020-03972-y · doi:10.1007/s10096-020-03972-y
- Byrne, 2020, Saliva alternative to upper respiratory swabs for SARS-CoV-2 diagnosis, Emerg Infect Dis, 26, 2770, 10.3201/eid2611.203283 · doi:10.3201/eid2611.203283
- Güçlü, 2020, Comparison of saliva and oro-nasopharyngeal swab sample in the molecular diagnosis of COVID-19, Rev Assoc Med Bras (1992), 66, 1116, 10.1590/1806-9282.66.8.1116 · DOI
- Lin, 2020, Comparison of throat swabs and sputum specimens for viral nucleic acid detection in 52 cases of novel coronavirus (SARS-Cov-2)-infected pneumonia (COVID-19), Clin Chem Lab Med, 58, 1089, 10.1515/cclm-2020-0187 · DOI
- Moreno-Contreras, 2020, Saliva sampling and its direct lysis, an excellent option to increase the number of SARS-CoV-2 diagnostic tests in settings with supply shortages, J Clin Microbiol, 58, e01659-20, 10.1128/JCM.01659-20 · DOI
- Pasomsub, 2021, Saliva sample as a non-invasive specimen for the diagnosis of coronavirus disease 2019: a cross-sectional study, Clin Microbiol Infect, 27, 285.e1, 10.1016/j.cmi.2020.05.001 · DOI · Paper page
- Skolimowska, 2020, Non-invasive saliva specimens for the diagnosis of COVID-19: caution in mild outpatient cohorts with low prevalence, Clin Microbiol Infect, 26, 1711, 10.1016/j.cmi.2020.07.015 · DOI
- Vaz, 2020, Saliva is a reliable, non-invasive specimen for SARS-CoV-2 detection, Braz J Infect Dis, 24, 422, 10.1016/j.bjid.2020.08.001 · DOI
- Wehrhahn, 2020, Self-collection: an appropriate alternative during the SARS-CoV-2 pandemic, J Clin Virol, 128, 104417, 10.1016/j.jcv.2020.104417 · DOI
- Tu, 2020, Patient-collected tongue, nasal, and mid-turbinate swabs for SARS-CoV-2 yield equivalent sensitivity to health care worker collected nasopharyngeal swabs, 10.1101/2020.04.01.20050005 · doi:10.1101/2020.04.01.20050005
- Wehrhahn, 2020, Self-collection: an appropriate alternative during the SARS-CoV-2 pandemic, 10.1101/2020.04.09.20057901 · doi:10.1101/2020.04.09.20057901
- Kojima, 2020, Self-collected oral fluid and nasal swabs demonstrate comparable sensitivity to clinician collected nasopharyngeal swabs for Covid-19 detection, 10.1101/2020.04.11.20062372 · doi:10.1101/2020.04.11.20062372
- Kim, 2020, Viral load kinetics of SARS-CoV-2 infection in first two patients in Korea, J Korean Med Sci, 35, e86, 10.3346/jkms.2020.35.e86 · DOI · Paper page
- Yang, 2020, Comparative sensitivity of different respiratory specimen types for molecular diagnosis and monitoring of SARS-CoV-2 shedding, Innovation (N Y), 1, 100061
- Gao, 2020, Evaluation the auxiliary diagnosis value of antibodies assays for detection of novel coronavirus (SARS-Cov-2) causing an outbreak of pneumonia (COVID-19), medRxiv, 10.1101/2020.03.26.20042044 · doi:10.1101/2020.03.26.20042044
- Wang, 2020, Detection of SARS-CoV-2 in different types of clinical specimens, JAMA, 323, 1843
- Yu, 2020, Quantitative detection and viral load analysis of SARS-CoV-2 in infected patients, Clin Infect Dis, 71, 793, 10.1093/cid/ciaa345 · DOI · Paper page
- Tan, 2020, Viral kinetics and antibody responses in patients with COVID-19, medRxiv, 10.1101/2020.03.24.20042382 · DOI · Paper page
- Lin, 2020, Comparison of throat swabs and sputum specimens for viral nucleic acid detection in 52 cases of novel coronavirus (SARS-Cov-2) infected pneumonia (COVID-19), medRxiv, 10.1101/2020.02.21.20026187 · doi:10.1101/2020.02.21.20026187
- Ai, 2020, Analysis of factors associated early diagnosis in coronavirus disease 2019 (COVID-19), 10.1101/2020.04.09.20059352 · DOI
- Zhou, 2020, Clinical features and outcomes of 197 adult discharged patients with COVID-19 in Yichang, Hubei, 10.1101/2020.03.26.20041426 · DOI
- Bulterys, 2020, Comparison of a laboratory-developed test targeting the envelope gene with three nucleic acid amplification tests for detection of SARS-CoV-2, J Clin Virol, 129, 104427, 10.1016/j.jcv.2020.104427 · DOI
- Eckel, 2020, Variplex™ test system fails to reliably detect SARS-CoV-2 directly from respiratory samples without RNA extraction, Eur J Clin Microbiol Infect Dis, 39, 2373, 10.1007/s10096-020-03983-9 · doi:10.1007/s10096-020-03983-9
- Harrington, 2020, Comparison of Abbott ID Now and Abbott m2000 methods for the detection of SARS-CoV-2 from nasopharyngeal and nasal swabs from symptomatic patients, J Clin Microbiol, 58, 10.1128/JCM.00798-20 · DOI · Paper page
- Hogan, 2020, Comparison of the accula SARS-CoV-2 test with a laboratory-developed assay for detection of SARS-CoV-2 RNA in clinical nasopharyngeal specimens, J Clin Microbiol, 58, e01072-20, 10.1128/JCM.01072-20 · DOI
- Hou, 2020, Multicenter evaluation of the cepheid Xpert Xpress SARS-CoV-2 assay for the detection of SARS-CoV-2 in oropharyngeal swab specimens, J Clin Microbiol, 58, e01288-20, 10.1128/JCM.01288-20 · DOI
- Lieberman, 2020, Comparison of commercially available and laboratory-developed assays for in vitro detection of SARS-CoV-2 in clinical laboratories, J Clin Microbiol, 58, e00821-20, 10.1128/JCM.00821-20 · DOI · Paper page
- Liotti, 2020, Evaluating the newly developed BioFire COVID-19 test for SARS-CoV-2 molecular detection, Clin Microbiol Infect, 26, 1699, 10.1016/j.cmi.2020.07.026 · DOI
- Loeffelholz, 2020, Multicenter evaluation of the cepheid Xpert Xpress SARS-CoV-2 test, J Clin Microbiol, 58, e00926-20, 10.1128/JCM.00926-20 · DOI · Paper page
- McDonald, 2020, Diagnostic performance of a rapid point-of-care test for SARS-CoV-2 in an Urban Emergency Department Setting, Acad Emerg Med, 27, 764, 10.1111/acem.14039 · DOI
- Mitchell, 2020, Evaluation of the COVID19 ID NOW EUA assay, J Clin Virol, 128, 104429, 10.1016/j.jcv.2020.104429 · DOI
- Moore, 2020, Comparison of two commercial molecular tests and a laboratory-developed modification of the CDC 2019-nCoV reverse transcriptase PCR assay for the detection of SARS-CoV-2, Clin Microbiol, 58, e00938-20, 10.1128/JCM.00938-20 · DOI
- Moran, 2020, Detection of SARS-CoV-2 by use of the Cepheid Xpert Xpress SARS-CoV-2 and Roche cobas SARS-CoV-2 assays, J Clin Microbiol, 58, e00772-20, 10.1128/JCM.00772-20 · DOI
- Smith, 2020, Analytical and clinical comparison of three nucleic acid amplification tests for SARS-CoV-2 detection, J Clin Microbiol, 58, e01134-20, 10.1128/JCM.01134-20 · doi:10.1128/jcm.01134-20
- Smithgall, 2020, Comparison of Cepheid Xpert Xpress and Abbott ID Now to Roche cobas for the rapid detection of SARS-CoV-2, J Clin Virol, 128, 104428, 10.1016/j.jcv.2020.104428 · DOI · Paper page
- Stevens, 2020, Comparison of a point-of-care assay and a high-complexity assay for detection of SARS-CoV-2 RNA, J Appl Lab Med, 5, 1307, 10.1093/jalm/jfaa135 · DOI
- Thwe, 2020, How many are we missing with ID NOW COVID-19 assay using direct nasopharyngeal swabs? Findings from a mid-sized academic hospital clinical microbiology laboratory, Diagn Microbiol Infect Dis, 98, 115123, 10.1016/j.diagmicrobio.2020.115123 · DOI
- Visseaux, 2020, Evaluation of the QIAstat-Dx respiratory SARS-CoV-2 panel, the first rapid multiplex PCR commercial assay for SARS-CoV-2 detection, J Clin Microbiol, 58, e00630-20, 10.1128/JCM.00630-20 · DOI
- Wolters, 2020, Multi-center evaluation of cepheid xpert® xpress SARS-CoV-2 point-of-care test during the SARS-CoV-2 pandemic, J Clin Virol, 128, 104426, 10.1016/j.jcv.2020.104426 · DOI
- Zhen, 2020, Clinical evaluation of three sample-to-answer platforms for detection of SARS-CoV-2, J Clin Microbiol, 58, e00783-20, 10.1128/JCM.00783-20 · DOI · Paper page
- Hu, 2020, Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China, 10.1101/2020.02.20.20025619 · DOI
- Zou, 2020, SARS-CoV-2 viral load in upper respiratory specimens of infected patients, N Engl J Med, 382, 1177, 10.1056/NEJMc2001737 · DOI · Paper page
- Danis, 2020, Cluster of coronavirus disease 2019 (Covid-19) in the French Alps, 2020, Clin Infect Dis, 10.1093/cid/ciaa424 · DOI · Paper page
- Bi, 2020, Epidemiology and transmission of COVID-19 in Shenzhen China: analysis of 391 cases and 1286 of their close contacts, 10.1101/2020.03.03.20028423 · DOI
- Wei, 2020, Presymptomatic transmission of SARS-CoV-2—Singapore, January 23-March 16, 2020, MMWR Morb Mortal Wkly Rep, 69, 411, 10.15585/mmwr.mm6914e1 · DOI · Paper page
- Kimball, 2020, Asymptomatic and presymptomatic SARS-CoV-2 infections in residents of a long-term care skilled nursing facility—King County, Washington, March 2020, MMWR Morb Mortal Wkly Rep, 69, 377, 10.15585/mmwr.mm6913e1 · DOI · Paper page
- Gostic, 2020, Estimated effectiveness of symptom and risk screening to prevent the spread of COVID-19, eLife, 9, e55570, 10.7554/eLife.55570 · DOI · Paper page
- Folgueira, 2020, SARS-CoV-2 infection in Health Care Workers in a large public hospital in Madrid, Spain, during March 2020, 10.1101/2020.04.07.20055723 · DOI
- Lu, 2020, COVID-19 outbreak associated with air conditioning in restaurant, Guangzhou, China, 2020, Emerg Infect Dis, 26, 1628, 10.3201/eid2607.200764 · DOI · Paper page
- Yu, 2020, SARS-CoV-2 transmission in cancer patients of a tertiary hospital in Wuhan, 10.1101/2020.02.22.20025320 · doi:10.1101/2020.02.22.20025320
- Waghmare, 2020, Guidelines for COVID-19 management in hematopoietic cell transplantation and cellular therapy recipients, Biol Blood Marrow Transplant, 26, 1983, 10.1016/j.bbmt.2020.07.027 · DOI
- 2020, Special considerations in solid organ transplant, hematopoietic stem cell transplant, and cellular therapy candidates, donors, and recipients
- Ljungman, 2020, The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy, Bone Marrow Transplant, 55, 2071, 10.1038/s41409-020-0919-0 · DOI · Paper page
- Abbas, 2017, Respiratory viruses in transplant recipients: more than just a cold. Clinical syndromes and infection prevention principles, Int J Infect Dis, 62, 86, 10.1016/j.ijid.2017.07.011 · doi:10.1016/j.ijid.2017.07.011
- Pochon, 2018, Respiratory virus infections in hematopoietic cell transplant recipients, Front Microbiol, 9, 3294, 10.3389/fmicb.2018.03294 · DOI
- Gallo, 2020, Cancer population may be paradoxically protected from severe manifestations of COVID-19, J Infect, 81, e156, 10.1016/j.jinf.2020.06.011 · DOI
- Li, 2020, Cancer increases risk of in-hospital death from COVID-19 in persons <65 years and those not in complete remission, Leukemia, 34, 2384, 10.1038/s41375-020-0986-7 · DOI
- Miyashita, 2020, Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City, Ann Oncol, 31, 1088, 10.1016/j.annonc.2020.04.006 · DOI · Paper page
- Pinto, 2020, SARS-CoV-2 positive hospitalized cancer patients during the Italian outbreak: the Cohort Study in Reggio Emilia, Biology, 9, 181, 10.3390/biology9080181 · DOI
- Sanchez-Pina, 2020, Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies, Eur J Haematol, 105, 597, 10.1111/ejh.13493 · DOI
- Shah, 2020, Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King’s College Hospital experience, Br J Haematol, 190, e279, 10.1111/bjh.16935 · DOI
- Stroppa, 2020, Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy), Future Oncol, 16, 1425, 10.2217/fon-2020-0369 · DOI
- Tian, 2020, Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study, Lancet Oncol, 21, 893, 10.1016/S1470-2045(20)30309-0 · DOI · Paper page
- Yigenoglu, 2021, The outcome of COVID-19 in patients with hematological malignancy, J Med Virol, 93, 1099, 10.1002/jmv.26404 · DOI
- Aries, 2020, Clinical outcome of coronavirus disease 2019 in haemato-oncology patients, Br J Haematol, 190, e64-e7, 10.1111/bjh.16852 · DOI
- Assaad, 2020, High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR, Eur J Cancer, 135, 251, 10.1016/j.ejca.2020.05.028 · DOI
- Dufour, 2020, COVID-19, impact on myeloma patients, Ann Hematol, 99, 1947, 10.1007/s00277-020-04147-7 · DOI
- Engelhardt, 2020, Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany, Haematologica, 105, 2872, 10.3324/haematol.2020.262758 · DOI
- Garassino, 2020, COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study, Lancet Oncol, 21, 914, 10.1016/S1470-2045(20)30314-4 · DOI · Paper page
- Infante, 2020;, COVID-19 in patients with hematological malignancies: a retrospective case series, Int J Lab Hematol, 10.1111/ijlh.13301 · DOI
- Jee, 2020, Chemotherapy and COVID-19 outcomes in patients with cancer, J Clin Oncol, 38, 3538, 10.1200/JCO.20.01307 · DOI · Paper page
- Lee, 2020, COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study, Lancet Oncol, 21, 1309, 10.1016/S1470-2045(20)30442-3 · DOI · Paper page
- Liang, 2020, Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China, Lancet Oncol, 21, 335, 10.1016/S1470-2045(20)30096-6 · DOI · Paper page
- Mehta, 2020, Case fatality rate of cancer patients with COVID-19 in a New York Hospital System, Cancer Discov, 10, 935, 10.1158/2159-8290.CD-20-0516 · DOI · Paper page
- Passamonti, 2020, Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study, Lancet Haematol, 7, e737, 10.1016/S2352-3026(20)30251-9 · DOI · Paper page
- Pinato, 2020, Presenting features and early mortality from SARS-CoV-2 infection in cancer patients during the initial stage of the COVID-19 pandemic in Europe, Cancers, 12, 1841, 10.3390/cancers12071841 · DOI
- Pinato, 2020, Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients, Cancer Discov, 10, 1465, 10.1158/2159-8290.CD-20-0773 · DOI · Paper page
- Robilotti, 2020, Determinants of COVID-19 disease severity in patients with cancer, Nat Med, 26, 1218, 10.1038/s41591-020-0979-0 · DOI · Paper page
- Song, 2020, Clinical characteristics of four cancer patients with SARS-CoV-2 infection in Wuhan, China, Infect Dis Poverty, 9, 82, 10.1186/s40249-020-00707-1 · doi:10.1186/s40249-020-00707-1
- Yang, 2020, Clinical characteristics and outcomes of cancer patients with COVID-19, J Med Virol, 92, 2067, 10.1002/jmv.25972 · DOI · Paper page
- Yarza, 2020, SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death, Eur J Cancer, 135, 242, 10.1016/j.ejca.2020.06.001 · DOI
- Zhang, 2020, Outcomes of novel coronavirus disease 2019 (COVID-19) infection in 107 patients with cancer from Wuhan, China, Cancer, 126, 4023, 10.1002/cncr.33042 · DOI
- Zhang, 2020, Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China, Ann Oncol, 31, 894, 10.1016/j.annonc.2020.03.296 · DOI · Paper page
- Treon, 2020, The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients, Blood, 135, 1912, 10.1182/blood.2020006288 · DOI · Paper page
- Thibaud, 2020, Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19, Br J Haematol, 190, e73, 10.1111/bjh.16863 · DOI
- Montopoli, 2020, Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532), Ann Oncol, 31, 1040, 10.1016/j.annonc.2020.04.479 · DOI · Paper page
- Montero, 2020, Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes, Rheumatol Int, 40, 1593, 10.1007/s00296-020-04676-4 · DOI
- Pablos, 2020, Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases, Ann Rheum Dis, 79, 1170, 10.1136/annrheumdis-2020-217763 · DOI
- Santos, 2020, Determinants of COVID-19 disease severity in patients with underlying rheumatic disease, Clin Rheumatol, 39, 2789, 10.1007/s10067-020-05301-2 · DOI
- Scirè, 2020, COVID-19 in rheumatic diseases in Italy: first results from the Italian registry of the Italian Society for Rheumatology (CONTROL-19), Clin Exp Rheumatol, 38, 748
- Winthrop, 2021, SARS CoV-2 infection among patients using immunomodulatory therapies, Ann Rheum Dis, 80, 269, 10.1136/annrheumdis-2020-218580 · doi:10.1136/annrheumdis-2020-218580
- Zen, 2020, SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: a cross-sectional study on 916 patients, J Autoimmun, 112, 102502, 10.1016/j.jaut.2020.102502 · doi:10.1016/j.jaut.2020.102502
- Zhao, 2020, Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China ‘hot spot’ versus in US ‘hot spot’: similarities and differences, Ann Rheum Dis, 10.1136/annrheumdis-2020–218183 · doi:10.1136/annrheumdis-2020-218183
- Emmi, 2020, SARS-CoV-2 infection among patients with systemic autoimmune diseases, Autoimmun Rev, 19, 102575, 10.1016/j.autrev.2020.102575 · DOI
- Fernandez-Ruiz, 2020, Leveraging the United States epicenter to provide insights on COVID-19 in patients with systemic lupus erythematosus, Arthritis Rheumatol, 72, 1971, 10.1002/art.41450 · DOI
- Freites Nuñez, 2020, Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases, Ann Rheum Dis, 79, 1393, 10.1136/annrheumdis-2020-217984 · DOI · Paper page
- Gartshteyn, 2020, COVID-19 and systemic lupus erythematosus: a case series, Lancet Rheumatol, 2, e452, 10.1016/S2665-9913(20)30161-2 · doi:10.1016/s2665-9913(20)30161-2
- Kumar, 2020, COVID-19 in rheumatic diseases: a random cross-sectional telephonic survey, medRxiv, 10.1101/2020.08.09.20170985 · DOI
- Huang, 2020, Clinical characteristics of 17 patients with COVID-19 and systemic autoimmune diseases: a retrospective study, Ann Rheum Dis, 79, 1163, 10.1136/annrheumdis-2020-217425 · doi:10.1136/annrheumdis-2020-217425
- D’Silva, 2020, Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US ‘hot spot’, Ann Rheum Dis, 79, 1156, 10.1136/annrheumdis-2020-217888 · DOI · Paper page
- Queiro Silva, 2020, COVID-19 patients with psoriasis and psoriatic arthritis on biologic immunosuppressant therapy vs apremilast in North Spain, Dermatol Ther, 33, e13961, 10.1111/dth.13961 · doi:10.1111/dth.13961
- Strippoli, 2020, Biologic agents in psoriasis: our experience during coronavirus infection, Int J Dermatol, 59, e266, 10.1111/ijd.15002 · DOI
- Fougerousse, 2020, Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19, J Eur Acad Dermatol Venereol, 34, e676, 10.1111/jdv.16761 · doi:10.1111/jdv.16761
- Gisondi, 2020, The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience, Br J Dermatol, 183, 373, 10.1111/bjd.19158 · doi:10.1111/bjd.19158
- Damiani, 2020, Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration, Dermatol Ther, 33, e13475, 10.1111/dth.13475 · doi:10.1111/dth.13475
- Parrotta, 2020, COVID-19 outcomes in MS: Observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center, Neurol Neuroimmunol Neuroinflamm, 7, e835, 10.1212/NXI.0000000000000835 · DOI
- Fan, 2020, Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders, Neurol Neuroimmunol Neuroinflamm, 7, e787, 10.1212/NXI.0000000000000787 · DOI
- Norsa, 2020, Uneventful course in patients with inflammatory bowel disease during the severe acute respiratory syndrome coronavirus 2 outbreak in Northern Italy, Gastroenterology, 159, 371, 10.1053/j.gastro.2020.03.062 · DOI
- Scaldaferri, 2020, Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: reorganisational response in a high-volume Italian inflammatory bowel disease centre, United European Gastroenterol J, 8, 775, 10.1177/2050640620929133 · doi:10.1177/2050640620929133
- Allocca, 2020, Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the nancy and milan cohorts, Clin Gastroenterol Hepatol, 18, 2134, 10.1016/j.cgh.2020.04.071 · DOI
- Rodríguez-Lago, 2020, Characteristics and prognosis of patients with inflammatory bowel disease during the SARS-CoV-2 pandemic in the Basque Country (Spain), Gastroenterology, 159, 781, 10.1053/j.gastro.2020.04.043 · DOI
- Taxonera, 2020, 2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases, Aliment Pharmacol Ther, 52, 276, 10.1111/apt.15804 · DOI · Paper page
- Gubatan, 2020, SARS-CoV-2 testing, prevalence, and predictors of COVID-19 in patients with inflammatory bowel disease in Northern California, Gastroenterology, 159, 1141, 10.1053/j.gastro.2020.05.009 · DOI
- Bezzio, 2020, Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study, Gut, 69, 1213, 10.1136/gutjnl-2020-321411 · DOI · Paper page
- Khan, 2020, Impact of anti-tumor necrosis factor and thiopurine medications on the development of COVID-19 in patients with inflammatory bowel disease: a nationwide veterans administration cohort study, Gastroenterology, 159, 1545, 10.1053/j.gastro.2020.05.065 · DOI
- Marafini, 2020, Low frequency of COVID-19 in inflammatory bowel diseases, Dig Liver Dis, 52, 1234, 10.1016/j.dld.2020.06.007 · doi:10.1016/j.dld.2020.06.007
- Lukin, 2020, Baseline disease activity and steroid therapy stratify risk of COVID-19 in patients with inflammatory bowel disease, Gastroenterology, 159, 1541, 10.1053/j.gastro.2020.05.066 · DOI
- Maus, 2020, Infections associated with the new ‘nibs and mabs’ and cellular therapies, Curr Opin Infect Dis, 33, 281, 10.1097/QCO.0000000000000656 · DOI
- Lei, 2020, Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection, EClinicalMedicine, 21, 100331, 10.1016/j.eclinm.2020.100331 · DOI · Paper page
- Winichakoon, 2020, Negative nasopharyngeal and oropharyngeal swabs do not rule out COVID-19, J Clin Microbiol, 58, e00297-20, 10.1128/JCM.00297-20 · DOI · Paper page
- Zhou, 2020, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, 395, 1054, 10.1016/S0140-6736(20)30566-3 · DOI · Paper page
Cited by
Severe covid-19 pneumonia: pathogenesis and clinical management
Attaway, A. H., Scheraga, R. G., Bhimraj, A., Biehl, M., & Hatipoğlu, U. (2021) · BMJ · doi:10.1136/bmj.n436 · Cited by 437
Self-citationSafiabadi Tali, S. H., LeBlanc, J. J., Sadiq, Z., Oyewunmi, O. D., Camargo, C., Nikpour, B., Armanfard, N., Sagan, S. M., & Jahanshahi-Anbuhi, S. (2021) · Clinical Microbiology Reviews · doi:10.1128/cmr.00228-20 · Cited by 405
Post-COVID-19 fatigue: a systematic review
Joli, J., Buck, P., Zipfel, S., & Stengel, A. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.947973 · Cited by 155
El Mikati, I. K., Morgan, R. L., Murad, M. H., Sultan, S., Falck-Ytter, Y., & Mustafa, R. A. (2023) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2023.01.020 · Cited by 6
Self-citation
Metadata
- Authors
- Hanson, K. E., Caliendo, A. M., Arias, C. A., Hayden, M. K., Englund, J. A., Lee, M. J., Loeb, M., Patel, R., El Alayli, A., Altayar, O., Patel, P., Falck-Ytter, Y., Lavergne, V., Morgan, R. L., Murad, M. H., Sultan, S., Bhimraj, A., & Mustafa, R. A.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-01-22
- Volume
- 78
- Issue
- 7
- Pages
- e170-e207
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W3122661585
- Cited by
- 180
- References
- 16
- FWCI
- 12.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- Funders
- Centers for Disease Control and Prevention (6 NU50CK000477-04-01)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Molecular Diagnostic Testing (January 2021). https://app.cochat.ai/papers/10.1093/cid/ciab048
- The paper
- Hanson, K. E., Caliendo, A. M., Arias, C. A., Hayden, M. K., Englund, J. A., Lee, M. J., Loeb, M., Patel, R., El Alayli, A., Altayar, O., Patel, P., Falck-Ytter, Y., Lavergne, V., Morgan, R. L., Murad, M. H., Sultan, S., Bhimraj, A., & Mustafa, R. A. (2024). The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Molecular Diagnostic Testing (January 2021). Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciab048
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.